AJMC news story
The combination of long-acting cabotegravir with rilpivirine (CAB+RPV LA) has been used as a method of treating HIV. The injections can be received either monthly or every other month, potentially making them an appealing alternative to daily pills due to its persistent efficacy. In posters presented during CROI 2026, researchers evaluated whether treatment-naive patients prefer the CAB+RPV LA treatment to daily pills (VOLITION study) and how effective it was in patients with viral loads of 50 copies/mL or more compared with patients with less than 50 copies/mL (OPERA study).
Read the full news story here.
View all AJMC reports from CROI 2026
Source : AJMC
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.